ClinicalTrials.Veeva

Menu

HANSE - Holistic Implementation Study Assessing a Northern German Interdisciplinary Lung Cancer Screening Effort

H

Hannover Medical School (MHH)

Status

Active, not recruiting

Conditions

Lung Cancer

Treatments

Radiation: Low-dose CT screening

Study type

Interventional

Funder types

Other

Identifiers

NCT04913155
ESR-20-20770

Details and patient eligibility

About

The HANSE study is primarily intended as a pilot to provide evidence that a holistic and effective lung cancer screening program can be implemented in Germany and that such a screening program can be integrated in the current infrastructure of certified lung cancer centers.

Full description

Germany has a long history of offering screening programs for cancers, such as breast, colorectal, and, more recently, cervical and skin cancer. Screening for lung cancer, however, which causes more deaths than any other cancer in men and is the second leading cancer death in women (not far behind breast cancer), has not been implemented to date. Only very recently, Institute for Quality and Efficiency in Healthcare (IQWiG) in a preliminary assessment of low-dose CT screening, concluded that the benefits from screening outweigh potential risks. However, an implementation of a national lung cancer screening program, which would be covered by the general health insurance, will likely not be implemented before 2022.

Nonetheless, the IQWiG report also comments on important criteria for implementing lung cancer screening in Germany using low-dose CT:

  1. It would be necessary to determine criteria that define a high-risk population. Various risk forecasting models are currently being propagated to enable a more precise selection of high-risk individuals. Their reliability and repeatability needs to be checked.
  2. Integration of access to a smoking cessation program.
  3. Quality assurance measures must be taken into account, including standardized protocols for the evaluation of the CT images and the subsequent follow-up checks as well as the invasive diagnostic tissue sampling procedures. The HANSE study is primarily intended as a pilot to provide evidence that a holistic and effective lung cancer screening program can be implemented in Germany and that such a screening program can be integrated in the current infrastructure of certified lung cancer centers.

Enrollment

12,100 estimated patients

Sex

All

Ages

55 to 79 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  1. Male and female subjects aged 55-79 years
  2. Current or former smokers
  3. Subjects with calculated risk score PLCOM2012 ≥1.58% (6 yrs.) or NELSON inclusion criteria (current or former smokers [those who had quit ≤10 years ago] who had smoked >15 cigarettes a day for >25 years or >10 cigarettes a day for >30 years).
  4. Able and willing to give written informed consent In addition, non-qualifying subjects fulfilling inclusion criteria 1 (age), 2 (smoking history) and 4 (consent), but do not meet the inclusion criterion 3 (risk too low) will be asked to volunteer by contributing long-term outcome data informing of the development of lung cancer or death from lung cancer (about n=7100 randomly selected from all 3 centers, low-risk group). These subjects will be contacted via mail after a minimum of 5 year follow up to inquire if they developed lung cancer in the time between their recruitment and present. Non-responders will be followed by local registries and by phone. New lung cancer cases will be verified using official hospital or cancer registry documents.

Exclusion criteria

  1. Comorbidity, which would unequivocally contraindicate either screening or treatment if lung cancer is detected.

  2. History of chest CT within the past year preceding the invitation.

  3. Inability to undergo non-contrast CT (e.g. ≥ 200 kg body weight, inability to lie flat).

  4. Pregnancy

  5. Risk of non-compliance with study procedures.

    • Unable to give written consent
    • Patient's inability to fill in the questionnaire self-dependent
    • Limited knowledge of the German language
    • Inability to travel, residents of care facilities, etc.

Trial design

Primary purpose

Screening

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

12,100 participants in 5 patient groups

Reporting group (coronary calcium score and emphysema score)
Other group
Description:
Coronary calcium score and emphysema score are reported to subjects
Treatment:
Radiation: Low-dose CT screening
Reporting group (coronary calcium score only)
Other group
Description:
Only coronary calcium score is reported to subjects
Treatment:
Radiation: Low-dose CT screening
Reporting group (emphysema score only)
Other group
Description:
Only emphysema score is reported to subjects
Treatment:
Radiation: Low-dose CT screening
Non-reporting group
Other group
Description:
Coronary calcium score and emphysema score are not reported to subjects
Treatment:
Radiation: Low-dose CT screening
Low-risk group
No Intervention group
Description:
No CT screening, collection of health data only

Trial documents
2

Trial contacts and locations

3

Loading...

Central trial contact

Jens Vogel-Claussen, Prof. Dr.; Heiko Hartleb

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems